In silico design and evaluation of a multiepitope vaccine targeting the nucleoprotein of Puumala orthohantavirus

The Puumala orthohantavirus is present in the body of the bank vole (Myodes glareolus). Humans infected with this virus may develop hemorrhagic fever accompanying renal syndrome. In addition, the infection may further lead to the failure of an immune system completely. The present study aimed to pro...

Full description

Saved in:
Bibliographic Details
Published in:Proteins, structure, function, and bioinformatics structure, function, and bioinformatics, 2024-10, Vol.92 (10), p.1161-1176
Main Authors: Bhattacharya, Kunal, Chanu, Nongmaithem Randhoni, Jha, Saurav Kumar, Khanal, Pukar, Paudel, Keshav Raj
Format: Article
Language:English
Subjects:
B and T‐cells
Bioinformatics
E coli
Epitopes
Hantavirus
Hemorrhagic fever with renal syndrome
Immune response
Immune system
Immunogenicity
immunoinformatics
Immunology
molecular docking
multiepitope vaccine
pET‐9c vector
Puumala orthohantavirus
Puumala virus
Renal failure
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Puumala orthohantavirus is present in the body of the bank vole (Myodes glareolus). Humans infected with this virus may develop hemorrhagic fever accompanying renal syndrome. In addition, the infection may further lead to the failure of an immune system completely. The present study aimed to propose a possible vaccine by employing bioinformatics techniques to identify B and T‐cell antigens. The best multi‐epitope of potential immunogenicity was generated by combining epitopes. Additionally, the linkers EAAAK, AAY, and GPGPG were utilized in order to link the epitopes successfully. Further, C‐ImmSim was used to perform in silico immunological simulations upon the vaccine. For the purpose of conducting expression tests in Escherichia coli, the chimeric protein construct was cloned using Snapgene into the pET‐9c vector. The designed vaccine showed adequate results, evidenced by the global population coverage and favorable immune response. The developed vaccine was found to be highly effective and to have excellent population coverage in a number of computer‐based assessments. This work is fully dependent on the development of nucleoprotein‐based vaccines, which would constitute a significant step forward if our findings were used in developing a global vaccination to combat the Puumala virus.
ISSN:0887-3585
1097-0134
1097-0134
DOI:10.1002/prot.26703